June 5, 2023

F1 Oncology announces development milestone and $10M equity investment

Pin It

From F1 Oncology Precision medicine-directed trial of AXL and ROR2 targeted conditionally active CAR-T cellular products to enroll patients with refractory, metastatic kidney cancer IMAGE: (PRNewsfoto/F1 Oncology) SHANGHAI and WEST PALM BEACH, Fla., Jan. 7, 2018 /PRNewswire/ — F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, today announced […]